CLEVELAND, Ohio — Researchers at Case Western Reserve University School of Medicine and MetroHealth System have developed a ...
An exploratory analysis of the phase 2 ALYCANTE trial (NCT04531046) reveals that patients with relapsed/refractory large ...
Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.
Clinical trials provide patients with relapsed or treatment-resistant lymphoma access to emerging therapies, making conversations with providers essential, according to Dr. Jennif ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...
Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...
Revuforj is approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older. The AUGMENT-101 trial showed a 21.2% complete remission rate with a median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results